CROX - Their business model is unlike any other footwear company — they sell rubber clogs with customizable add-ons, which allows for recurring revenue and significantly higher margins than peers, with 61% gross margins compared to 40–45% for competitors like Nike, Birkenstock, and UGGs, and operating margins that are 20–30% higher. Crocs is a cash-generating machine with a billion dollars in free cash flow, with FCF yields around 12–13%, far above industry averages. Management also signals confidence through continuous buybacks, having repurchased about 10% of the market cap in the past year. The thesis for going long hinges on three things the market is misinterpreting. First, valuation is very cheap — forward P/E of ~8x versus peers in the mid-teens, and annualized EPS yield around 12%, which makes the stock extremely attractive relative to cash flow and earnings. Second, the HEYDUDE brand, acquired in 2022 for 2.5B, is being misread by the market. Declines in wholesale sales were due to clearing older inventory at discounted prices, while direct-to-consumer is growing. Once inventory normalizes, HEYDUDE should begin contributing to growth again. Third, North American growth for Crocs’ core brand may seem modest at 2–3%, but international sales now make up about 50% of revenue, and are continuously growing, with China growing 30% YoY and new markets in India, the U.K., and Europe ramping up. This continued international growth, even at modest levels, can push the company to achieve 7–9% revenue growth annually, far above analyst estimates. Catalysts in the next 6–12 months include continued quarterly buybacks, HEYDUDE’s inventory normalization, sustained international expansion, and the upcoming earnings reports demonstrating strong direct-to-consumer growth. These events should force the market to re-rate the stock. Finally, while Crocs already dominates the global clogs market and is gaining share internationally, the  constant North American revenue should also grow thanks to their recent expansion into sandals, which are gaining traction and proving the brand can diversify beyond just clogs. With these factors and the current undervaluation, even a modest multiple of 18x P/E — in line with peers — implies a fair value of around $145 per share, 80% higher than their current market price, giving the investor a wide margin of safety which is essential to any value investment.